• 主题
高级搜索  >
历史搜索 清空历史
首页> 外国专利> Methods for treating a patient who has an ifn type i or ifnalfa-mediated disease or disorder, to counteract a differentially regulated myna marker profile in a patient, to monitor or predict a progression of a patient's inflammatory disease and myositis disease, to monitor the progression of a patient's inflammatory or autoimmune disease and myositis disease and to treat a patient with myositis

Methods for treating a patient who has an ifn type i or ifnalfa-mediated disease or disorder, to counteract a differentially regulated myna marker profile in a patient, to monitor or predict a progression of a patient's inflammatory disease and myositis disease, to monitor the progression of a patient's inflammatory or autoimmune disease and myositis disease and to treat a patient with myositis

机译：治疗患有ifn I型或ifnalfa介导的疾病或病症的患者的方法，以抵消患者体内差异调节的myna标志谱，监测或预测患者的炎性疾病和肌炎疾病的进展，以监测进展患者的炎性或自身免疫性疾病和肌炎疾病的治疗，以及治疗患有肌炎的患者

页面导航
  • 摘要
  • 著录项
  • 相似文献

摘要

A method of monitoring myositis disease progression of a patient receiving treatment with a therapeutic agent comprising (i) obtaining a first IFN±-inducible PD marker expression profile in a first sample from the patient; (ii) obtaining a second IFN±-inducible PD marker expression profile in a second sample from the patient after a therapeutic agent has been administered; and (iii) comparing the first and the second IFN±-inducible PD marker expression profiles, wherein the IFN±-inducible PD marker expression profile is based upon up-regulation of the expression of the following genes EPSTI1, HERC5, IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT3, ISG15, LAMP3, LY6E, MX1, OAS1, OAS2, OAS3, RSAD2, RTP4, SIGLEC1, and USP18; and wherein a variance in the first and the second IFN±-inducible PD marker expression profiles indicates a level of efficacy of the therapeutic agent, wherein the variance is a decrease in up-regulated expression of the gene.
机译：一种监测接受治疗剂治疗的患者的肌炎疾病进展的方法，该方法包括：（i）获得来自患者的第一样品中的第一IFN-诱导型PD标志物表达谱; （ii）在已经给予治疗剂后，从患者的第二个样品中获得第二个IFN±诱导型PD标记表达谱; （iii）比较第一和第二个IFN±诱导的PD标记表达谱，其中IFN±诱导的PD标记表达谱基于以下基因EPSTI1，HERC5，IFI27，IFI44的表达上调。 IFI44L，IFI6，IFIT1，IFIT3，ISG15，LAMP3，LY6E，MX1，OAS1，OAS2，OAS3，RSAD2，RTP4，SIGLEC1和USP18其中第一和第二IFN±可诱导的PD标志物表达概况的变化表明治疗剂的功效水平，其中该变化是基因上调表达的减少。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号